Daewoong sees highest patent filings and grants during July in Q3 2023
Daewoong saw the highest growth of 108% in patent filings in July and 266% in grants in August in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 108% and grants by 99%. GlobalData's DataBook provides a comprehensive analysis of Daewoong's patent filings and grants. Buy the databook here.Daewoong has been focused on protecting inventions in South Korea(KR) with 15 publications in Q3 2023The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 25% filings and 50% grants. The South Korea(KR), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Daewoong is filings its patents. Among the top granted patent authorities, Daewoong has 50% of its grants in South Korea(KR), 22% in European Patent Office(EPO), and 11% in Australia(AU).Johnson & Johnson could be the strongest competitor for DaewoongJohnson & Johnson and Pfizer secured the top positions according to recent patent publication data.Patents related to rare diseases and climate change lead Daewoong's portfolioDaewoong has the highest number of patents in rare diseases followed by, climate change and . For rare diseases, nearly 80% of patents were filed and 50% of patents were granted in Q3 2023.Fibrosis related patents lead Daewoong portfolio followed by hypertension, and hyperlipidemiaDaewoong has highest number of patents in fibrosis followed by hypertension, hyperlipidemia, obesity and triple-negative breast cancer (tnbc). For fibrosis, nearly 40% of patents were filed and 0% of patents were granted in Q3 2023.For comprehensive analysis of Daewoong's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for Daewoong here.
What's Your Reaction?
